HealthCare Royalty Partners (HCR) announced the closing of its latest fund, HealthCare Royalty Partners IV, with $1.83 billion, with new investors representing several of the world’s leading pensions, sovereign wealth funds, financial institutions, foundations and family offices.
The Stamford, Conn.-based $5.5 billion private debt firm uses debt-like structures to invest in commercial or near-commercial stage biopharmaceutical assets.Fund IV, like its predecessor funds will seed to provide returns that are non-correlated to the broader equity or credit markets. Since 2003, the firm has invested more than $3 billion in commercial . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
